A new phase 3 trial evaluated whether a quadrivalent modified mRNA influenza vaccine could match or exceed the efficacy of a licensed inactivated influenza vaccine in adults aged 18–64 years during the...
New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...
In this roundup, experts outline diverging pediatric COVID vaccine recommendations, midlife peaks in long COVID risk, new findings on abnormal uterine bleeding and cycle-related symptoms in long COVID, and...
From respiratory syncytial virus monoclonal antibody approvals to thimerosal-free vaccine preferences, ACIP’s latest guidance has important implications for your practice.
A randomized trial comparing influenza vaccines over two seasons found that recombinant vaccines showed stronger immune responses to A/H3N2 strains compared with egg-based and cell culture-based vaccines.
...
The Advisory Committee on Immunization Practices released its updated annual immunization schedule for 2024 that includes new sections on respiratory syncytial virus (RSV), and the mpox (monkeypox) and...
Researchers examined patterns among individuals who previously used preventative services and vaccinations and later vaccinations for both influenza and COVID-19 among US adults.
The CDC updated its guidance due to the United States seeing fewer hospitalizations associated with COVID-19 and because there are numerous tools to combat influenza, COVID-19, and respiratory syncytial...
Researchers studied the risk and prevalence of individuals developing varicella-zoster reactivation after receiving mRNA COVID-19 vaccination compared with receiving influenza vaccination. Their findings...
